The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Open accessAbstract
Detection of circulating tumor DNA in patients with resected stage II colon cancer provides evidence of residual disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a growing body of data demonstrating numerous clinical applications for ctDNA in adults with solid tumors, ranging from prognostication and evaluation of minimal residual disease (MRD) to detection of targetable alterations.7–12”
From Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study (2026) · cites this paper as [10]
In the citing paper
“A salient example of the well-established relationship between ctDNA burden and disease status in adult solid tumors is the use of ctDNA for MRD detection and monitoring for recurrence in colorectal cancers.10–12”
From Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study (2026) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citationTime‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & PEPE, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,870
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Self-citationCirculating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,746
Self-citationRibic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Self-citationSargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623
Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging
O'Connell, J. B., Maggard, M. A., & Ko, C. Y. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh275 · Cited by 1,598
The classification of cancer of the rectum
Dukes, C. (1932) · The Journal of Pathology and Bacteriology · doi:10.1002/path.1700350303 · Cited by 1,520
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
QUASAR Collaborative Group (2007) · The Lancet · doi:10.1016/s0140-6736(07)61866-2 · Cited by 1,435
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
García-Murillas, I., Schiavon, G., Weigelt, B., Ng, C. K. Y., Hrebien, S., Cutts, R. J., Cheang, M. C. U., Osin, P., Nerurkar, A. Y., Kozarewa, I., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab0021 · Cited by 1,174
Detection and quantification of rare mutations with massively parallel sequencing
Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W., & Vogelstein, B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105422108 · Cited by 1,144
Self-citationIntegrated digital error suppression for improved detection of circulating tumor DNA
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., Stehr, H., Liu, C. L., Bratman, S. V., Say, C., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3520 · Cited by 1,100
André, T., de Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A., Scriva, A., Hickish, T., Tabernero, J., Van Laethem, J. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4238 · Cited by 683
Follow-up strategies for patients treated for non-metastatic colorectal cancer
Jeffery, M., Hickey, B. E., Hider, P. N., & See, A. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002200.pub3 · Cited by 661
Renehan, A. G., Egger, M., Saunders, M. P., & O'Dwyer, S. T. (2002) · BMJ · doi:10.1136/bmj.324.7341.813 · Cited by 651
Shia, J. (2008) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.080031 · Cited by 644
Tie, J., Kinde, I., Wang, Y., Wong, H., Roebert, J. K., Christie, M., TACEY, M. A., Wong, R., Singh, M., Karapetis, C. S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv177 · Cited by 632
Self-citationEvolutionary dynamics of cancer in response to targeted combination therapy
Božić, I., Reiter, J. G., Allen, B., Tibor Antal, A., Chatterjee, K., Shah, P., Moon, Y. S., Yaqubie, A., Kelly, N. E., Le, D. T., et al. (2013) · eLife · doi:10.7554/elife.00747 · Cited by 623
Self-citationZhang, J., Wu, S., Chen, Z., Wei, J., Liao, Y.-J., Lei, J., Hu, M., Chen, G.-Z., Liao, B., Lü, J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70491-1 · Cited by 542
Mamounas, E. P., Wieand, S., Wolmark, N., Bear, H. D., Atkins, J. N., Song, K., Jones, J. M., & Rockette, H. E. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1349 · Cited by 527
Sausen, M., Phallen, J., Adleff, V., Jones, S., Leary, R. J., Barrett, M. T., Anagnostou, V., Parpart-Li, S., Murphy, D., Kay Li, Q., et al. (2015) · Nature Communications · doi:10.1038/ncomms8686 · Cited by 484
Self-citationAdjuvant Chemotherapy for Stage II Colon Cancer With Poor Prognostic Features
O’Connor, E. S., Greenblatt, D. Y., LoConte, N. K., Gangnon, R. E., Liou, J., Heise, C. P., & Smith, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3426 · Cited by 463
Follow-up of patients with curatively resected colorectal cancer: a practice guideline
Figueredo, A., Rumble, R. B., Maroun, J., Earle, C. C., Cummings, B., McLeod, R., Zuraw, L., Zwaal, C., & the members of the Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care (2003) · BMC Cancer · doi:10.1186/1471-2407-3-26 · Cited by 392
Gray, R. G., Quirke, P., Handley, K., Lopatin, M., Magill, L., Baehner, F. L., Beaumont, C., Clark-Langone, K. M., YOSHIZAWA, C. N., Lee, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8732 · Cited by 378
Figueredo, A. T., Charette, M. L., Maroun, J. A., Brouwers, M. C., & Zuraw, L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.087 · Cited by 346
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
Kinde, I., Bettegowda, C., Wang, Y., Wu, J., Agrawal, N., Shih, I.-M., Kurman, R., Dao, F., Levine, D. A., Giuntoli, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004952 · Cited by 327
Self-citationPita‐Fernández, S., Alhayek-Aí, M., González-Martín, C., López‐Calviño, B., Seoane‐Pillado, T., & Pértega-Díaz, S. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu543 · Cited by 260
Morelli, M. P., Overman, M. J., Dasari, A. N., Kazmi, S. M. A., Mazard, T., Vilar, E., Morris, V. K., Lee, M. S., Herron, D. S., Eng, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv005 · Cited by 256
Identification of Patients with High-Risk Stage II Colon Cancer for Adjuvant Therapy
Quah, H., Chou, J. F., Gönen, M., Shia, J., Schrag, D., Landmann, R., Guillem, J. G., Paty, P. B., Temple, L. K. F., Wong, W. D., et al. (2008) · Diseases of the Colon & Rectum · doi:10.1007/s10350-008-9246-z · Cited by 255
Follow-up strategies for patients treated for non-metastatic colorectal cancer
Jeffery, M., Hickey, B. E., & Hider, P. N. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002200.pub2 · Cited by 205
Venook, A. P., Niedzwiecki, D., Lopatin, M., Ye, X., Lee, M., Friedman, P. N., Frankel, W. L., Clark-Langone, K. M., Millward, C. L., Shak, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.1096 · Cited by 173
Follow-up strategies for patients treated for non-metastatic colorectal cancer
Jeffery, G. M., Hickey, B. E., & Hider, P. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002200 · Cited by 157
2000 Update of American Society of Clinical Oncology Colorectal Cancer Surveillance Guidelines
Benson, A. B., Desch, C. E., Flynn, P. J., Krause, C., Loprinzi, C. L., Minsky, B. D., Petrelli, N. J., Pfister, D. G., Smith, T. J., & Somerfield, M. R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3586 · Cited by 144
Kopetz, S., Tabernero, J. M., Rosenberg, R., Jiang, Z.-Q., Moreno, V. R., Bachleitner‐Hofmann, T., Lanza, G., Stork‐Sloots, L., Maru, D. M., Simón, I., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0325 · Cited by 130
Niedzwiecki, D., Bertagnolli, M. M., Warren, R. S., Compton, C. C., Kemeny, N. E., Benson, A. B., Eckhardt, S., Alberts, S. R., Porjosh, G. N., Kerr, R. S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5357 · Cited by 78
Chao, M., & Gibbs, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6156 · Cited by 46
Self-citationWirtzfeld, D. A., Mikula, L., Gryfe, R., Ravani, P., Dicks, E. L., Parfrey, P., Gallinger, S., & Pollett, W. G. (2009) · PubMed Central · Cited by 33
Flagged first, then by citations
2 of the 43 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- S. Edge D. R. Byrd C. C. Compton A. G. Fritz F. L. Greene A. Trotti AJCC Cancer Staging Manual (Springer New York 2010) 648 pp.
Cited by
Sorted by citations
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
Liu, J., Xiao, Q., Xiao, J., Niu, C., Li, Y., Zhang, X., Zhou, Z., Shu, G., & Yin, G. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00762-6 · Cited by 2,519
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Abbosh, C., Birkbak, N. J., Wilson, G. A., Jamal‐Hanjani, M., Constantin, T. P., Salari, R., Quesne, J. P. C. L., Moore, D. A., Veeriah, S., Rosenthal, R., et al. (2017) · Nature · doi:10.1038/nature22364 · Cited by 1,900
Current and future perspectives of liquid biopsies in genomics-driven oncology
Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0071-5 · Cited by 1,557
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Argilés, G., Tabernero, J., Labianca, R., Hochhauser, D., Salazar, R., Iveson, T., Laurent-Puig, P., Quirke, P., Yoshino, T., Taieb, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.022 · Cited by 1,375
Metadata
- Authors
- Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., Kosmider, S., Skinner, I., Wong, R., Steel, M., Tran, B., Desai, J., Jones, I., Haydon, A., Hayes, T., Price, T. J., Strausberg, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., & Gibbs, P.
- Affiliations
- The University of Melbourne (AU)
- Howard Hughes Medical Institute (US)
- Johns Hopkins University (US)
- PapGene (United States) (US)
- The Royal Melbourne Hospital (AU)
- Western Health (AU)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Eastern Health (AU)
- The Alfred Hospital (AU)
- Department of Medical Oncology, Warrnambool Hospital, Warrnambool, Victoria 3280, Australia.
- Department of Medical Oncology, Queen Elizabeth Hospital and University of Adelaide, Adelaide, South Australia 3174, Australia.
- Ludwig Cancer Research (US)
- Corresponding author
- Tie, Jeanne
- Wang, Yuxuan
- Vogelstein, Bert
- Gibbs, Peter
- ORCID
- Tie, Jeanne
- Wang, Yuxuan
- Tomasetti, Cristian
- Li, Lu
- Springer, Simeon
- Silliman, Natalie
- Tacey, Mark
- Wong, Hui-Li
- Christie, Michael
- Kosmider, Suzanne
- Skinner, Iain
- Wong, Rachel
- Steel, Malcolm
- Tran, Ben
- Desai, Jayesh
- Jones, Ian
- Haydon, Andrew
- Hayes, Theresa
- Diaz, Luis A.
- Papadopoulos, Nickolas
- Kinzler, Kenneth W.
- Vogelstein, Bert
- Gibbs, Peter
- Venue
- Science Translational Medicine
- Published
- 2016-07-06
- Volume
- 8
- Issue
- 346
- Pages
- 346ra92-346ra92
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5346159
- OpenAlex
- W2460179076
- Cited by
- 1,492
- References
- 43
- Citations by year
- 2026: 119 · 2025: 131 · 2024: 130 · 2023: 181 · 2022: 173 · 2021: 197 · 2020: 173 · 2019: 146 · 2018: 134 · 2017: 90 · 2016: 14
- FWCI
- 53.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Funders
- Virginia and D.K. Ludwig Fund for Cancer Research
- Conrad N. Hilton Foundation
- Sol Goldman Sequencing Facility at Johns Hopkins
- NIH (CA57345, R37-CA43460, U01-CA152753, P30-CA006973)
- Victorian Cancer Agency
- Victorian Cancer Agency Clinical Research Fellowship
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- circulating tumor DNA, stage II colon cancer, minimal residual disease, tumor recurrence prediction, adjuvant chemotherapy, liquid biopsy, recurrence-free survival, plasma biomarkers, resected colon cancer
- MeSH terms
- Circulating Tumor DNA, Colonic Neoplasms, Humans, Neoplasm Recurrence, Local, Neoplasm Staging, Prospective Studies, Proportional Hazards Models, Neoplasm, Residual, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
